Ultragenyx Pharmaceutical (NASDAQ:RARE) said its third quarter included two U.S. gene therapy approvals, a failed late-stage Angelman syndrome study, the termination of its Wilson disease program and restructuring actions intended to support GAAP profitability in 2027. Chief Executive Officer and President Emil Kakkis said the Food and Drug Administration approved GENGLYCOS for glycogen storage disease […]

Recursion Pharmaceuticals (NASDAQ:RXRX) reported updated clinical data for its investigational treatment for familial adenomatous polyposis, or FAP, along with early activity in its solid-tumor program REC-1245, partnership progress and an extension of its expected cash runway into 2029. The company also announced that its board unanimously appointed Fred Hassan as non-executive chair. Hassan previously served […]